Abstract:Background: Multiple myeloma (MM), characterized by the proliferation of clonal plasma B-cell in the bone marrow, is the second most common hematologic malignancy in the US. MM represents the final stage in a continuum of plasma cell dyscrasias, arising from the premalignant conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Despite therapeutic advances, MM remains incurable with the prognostic improvement observed only in a subset of patients. The variations in clinical course are largely caused by the underlying intertumoral heterogeneity between different patients. To further improve the clinical outcome of MM patients, biomarkers that can effectively stratified patients are critically needed for directing personalized treatment. In this study, we hypothesize that the magnitude of plasma B cell malignancy is a primary factor that determines the clinical phenotypes of MM patients, which can be reflected by gene expression in CD138+ cells. Methods: Using single-cell RNA sequencing (scRNA-seq) data, we develop a plasma B gene signature and apply it to gene expression profiles of CD138+ cells from MM patients (Figure 1 A). The resulting score, denoted as plasma B cell malignancy (PBM) score, indicates the degree of plasma B cell malignancy of MM samples with a higher value indicating higher malignancy status. Genomic and/or transcriptomic data from five MM studies (i.e., MMRF CoMMpass, UAMS, MAQC-II and APEX phase 3 trial and Chng study) were used to examine the associations between PBM score and known MM driver genes, and its clinical impact on MM progression and prognosis. Univariate and multivariate Cox regression models were constructed to evaluate the prognostic value of patient specific PBM scores when used alone or combined with established clinical factors. Results: Survival analysis indicates that the PBM score defined based on plasma B cell markers are significantly associated with patient overall survival. In contrast, gene signatures charactering other immune cells are less (other three B cell types) or not prognostic (non-B immune cell types) (Figure 1 B). Then we investigated the effects of PBM score on MM development and prognosis. Overall, a higher PBM score was significantly associated with a more advanced stage in the spectrum of plasma cell dyscrasias (all P < 0.05, Figure 1C). Higher PBM score was also associated with shorter overall survival (OS) in patients with MM (HR = 1.72, P < 0.001) (Figure 1D) and its prognostic effect was independent of the currently available clinical prognostic model, such as the International Staging System (ISS) (Figure 1E). Mutation status of TP53 gene has been found to be associated with patient prognosis. Investigations on the relationships between PBM score and MM driver genes found that the PBM score was significantly increased in patients carrying TP53 mutations compared to those with mild-type alleles. Of note, PBM scores could predict patients’ survival even among those who don't carry TP53 mutations, with log-rank P values of 0.002 (Figure 1F). The model based on the PBM score alone had a c-index of 0.62 to predict the OS of MM. The clinical model based on age, sex, race, and (ISS) stage had a c-index of 0.67 to predict OS. Incorporating PBM score into the models based on clinical factors significantly improved the prognostic performance of the models, with the c-index increased to 0.70 for the model that combined PBM and clinical factors (P < 0.001) (Figure 1G).Conclusions: There may be a clinical utility of the PBM score to predict MM outcomes in combination with more standard clinical parameters. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

[The Effect of Peripheral Blood Cell Score on the Prognosis of Multiple Myeloma Patients Treated with Bortezomib].

Haematopoietic Score for the Prognostic Evaluation of Multiple Myeloma Patients Undergoing First-line Treatment with a Bortezomib-based Regimen

Decreased peripheral blood lymphocyte-monocyte ratio and platelet-monocyte ratio and the Peripheral Blood Score model predict poor survival in peripheral T-cell lymphoma patients

Treatment and Prognostic Factors for Survival in Newly Diagnosed Multiple Myeloma Patients with Bortezomib and Dexamethasone Regimen: a Single Chinese Center Retrospective Study

Low Peripheral Blood B Lymphocyte Count Predict Poor Outcome in Patients with Multiple Myeloma

Impaired Plasma B Cell Markers in CD138+ Cells Predict Prognosis in Multiple Myeloma

Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients

[Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib].

Analysis of peripheral neuropathy following treatment with bortezomib in 114 newly-diagnosed multiple myeloma patients

Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma.

Analysis of Correlation between Blood Inflammation Indicators in Peripheral Blood and Prognosis of Patients with Multiple Myeloma

Peripheral Blood Absolute Lymphocyte Count, Absolute Monocyte Count and Their Ratio in Prognosis Prediction of Newly Diagnosed Multiple Myeloma

Improvement of survival in patients with newly diagnosed multiple myeloma treated by Bortezomib based chemotherapy

Effects of Bortezomib on Treg Cells in Multiple Myeloma and Its Relationship with Tumor Burden and Chemoresponse

Cytogenetic and Clinical Marks for Defining High-Risk Myeloma in the Context of Bortezomib Treatment

The clinical and laboratory features of 214 patients with multiple myeloma

A Retrospective Analysis: A Novel Index Predicts Survival and Risk-Stratification for Bone Destruction in 419 Newly Diagnosed Multiple Myelomas.

The Prognostic Impact of Multiparameter Flow Cytometry Immunophenotyping and Cytogenetic Aberrancies in Patients with Multiple Myeloma

Single-Agent Bortezomib Or Bortezomib-Based Regimens As Consolidation Therapy After Autologous Hematopoietic Stem Cell Transplantation In Multiple Myeloma: A Meta-Analysis Of Randomized Controlled Trials

Therapeutic Effect and Adverse Event Rate of Different Treatment Methods in Patients with Multiple Myeloma and Renal Insufficiency

Baseline Peripheral Neuropathy Was Associated with Age and a Prognostic Factor in Newly Diagnosed Multiple Myeloma Patients.